These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9815596)

  • 21. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
    Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
    Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
    Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
    Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors.
    Boinpally RR; Polin L; Zhou SL; Jasti BR; Wiegand RA; White K; Kushner J; Horwitz JP; Corbett TH; Parchment RE
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):25-33. PubMed ID: 12739061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
    Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
    Yamada Y; Tamura T; Yamamoto N; Shimoyama T; Ueda Y; Murakami H; Kusaba H; Kamiya Y; Saka H; Tanigawara Y; McGovren JP; Natsumeda Y
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):173-82. PubMed ID: 16308697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of a homologous series of benzonaphthyridine anti-cancer agents in mice: divergence between tumour and plasma pharmacokinetics.
    Lukka PB; Paxton JW; Kestell P; Baguley BC
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):151-60. PubMed ID: 22660735
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models.
    Peterson JK; Tucker C; Favours E; Cheshire PJ; Creech J; Billups CA; Smykla R; Lee FY; Houghton PJ
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6950-8. PubMed ID: 16203787
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Poly(N-vinylpyrrolidone)-block-poly(D,L-lactide) as a new polymeric solubilizer for hydrophobic anticancer drugs: in vitro and in vivo evaluation.
    Le Garrec D; Gori S; Luo L; Lessard D; Smith DC; Yessine MA; Ranger M; Leroux JC
    J Control Release; 2004 Sep; 99(1):83-101. PubMed ID: 15342183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Murine toxicology and pharmacokinetics of novel retinoic acid metabolism blocking agents.
    Patel JB; Khandelwal A; Chopra P; Handratta VD; Njar VC
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):899-905. PubMed ID: 17345084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
    Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
    Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1.
    Egorin MJ; Zuhowski EG; Rosen DM; Sentz DL; Covey JM; Eiseman JL
    Cancer Chemother Pharmacol; 2001 Apr; 47(4):291-302. PubMed ID: 11345645
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent.
    Chun AW; Cosenza SC; Taft DR; Maniar M
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):177-86. PubMed ID: 19466411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents.
    Wang H; Li M; Rhie JK; Hockenbery DM; Covey JM; Zhang R; Hill DL
    Cancer Chemother Pharmacol; 2005 Sep; 56(3):291-8. PubMed ID: 15883820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone.
    Gokhale PC; Pei J; Zhang C; Ahmad I; Rahman A; Kasid U
    Anticancer Res; 2001; 21(5):3313-21. PubMed ID: 11848489
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I and pharmacokinetic study of a stable, polyethylene-glycolated liposomal doxorubicin in patients with solid tumors: the relation between pharmacokinetic property and toxicity.
    Hong RL; Tseng YL
    Cancer; 2001 May; 91(9):1826-33. PubMed ID: 11335910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F; Culine S; Bressolle F; Astre C; Serre MP; Chevillard C; Fabbro M
    Clin Cancer Res; 2000 Jan; 6(1):57-63. PubMed ID: 10656432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High performance liquid chromatographic analysis and preclinical pharmacokinetics of the heteroarotinoid antitumor agent, SHetA2.
    Zhang Y; Hua Y; Benbrook DM; Covey JM; Dai G; Liu Z; Chan KK
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):561-9. PubMed ID: 16534614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of plasma protein binding displacement on the pharmacokinetics, tissue and tumor concentrations and efficacy of brequinar, a highly protein-bound antitumor agent.
    Aungst BJ; Blake JA; Rogers NJ; Dusak BA
    J Pharmacol Exp Ther; 1990 Apr; 253(1):230-6. PubMed ID: 2329509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical pharmacology of the novel antitumor agent adaphostin, a tyrphostin analog that inhibits bcr/abl.
    Li M; Wang H; Hill DL; Stinson S; Veley K; Grossi I; Peggins J; Covey JM; Zhang R
    Cancer Chemother Pharmacol; 2006 May; 57(5):607-14. PubMed ID: 16331493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.